|Bid||201.380 x 1000|
|Ask||201.460 x 900|
|Day's Range||196.460 - 201.480|
|52 Week Range||163.310 - 210.190|
|Beta (3Y Monthly)||1.53|
|PE Ratio (TTM)||60.33|
|Earnings Date||Oct 30, 2018|
|Forward Dividend & Yield||5.28 (2.67%)|
|1y Target Est||205.15|
just after drug companies announced they will be disclosing prices of drugs advertised on TV via a website, the Trump administration proposes a rule to require medicare and medicaid drugs to disclose price in TV ads.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 15) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...
Rival versions of the world’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States. Amgen is rolling out its so-called biosimilar form of Humira, branded as Amgevita, across Europe from Oct. 16, while Novartis said its Sandoz unit was launching its product Hyrimoz initially in Britain, with other markets set to follow. Large sums are at stake, since Humira clocked up worldwide sales of $18 billion last year, of which around $4 billion came from Europe, and European healthcare administrators are eager to exploit the competitive situation to drive down drug bills.
Cheaper copies of the world’s biggest-selling drug will roll out across Europe this week after a key European patent for Humira expires Tuesday, but U.S. patients and insurers will have to wait to access less-expensive versions of the blockbuster drug. Inc., that prevents the developers of “biosimilar” versions launching their products in the U.S. Biosimilars are near-copies of biologic drugs, such as Humira, that are made from living cells in a process that resembles brewing.
THOUSAND OAKS, Calif., Oct. 15, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC).
Immune Design (IMDZ) to discontinue the CMB305 cancer vaccine program and focus on the development of its lymphoma therapy, G100.
AbbVie (ABBV) strikes a deal with Sandoz, the generic arm of Novartis, to launch its biosimilar Humira in the United States on Sep 30, 2023.
Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG, granting it a non-exclusive license to manufacture and sell a copycat version of blockbuster drug, Humira. Abbvie, however, did not disclose details regarding the royalties it will receive from Novartis generics unit, Sandoz, as part of the agreement. Shares of Abbvie rose 2.39 percent to $92.87 in after-market trading.
Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.
How's Celgene Positioned before Its Third-Quarter Earnings? Celgene’s (CELG) hematology and oncology franchise consists of Revlimid, Pomalyst, Abraxane, Idhifa, Vidaza, Istodax, and Thalomid. Revlimid’s revenues grew from $3.9 billion in the first half of 2017 to $4.7 billion in the first half of 2018, which reflects ~19.6% growth YoY (year-over-year).